← All trials
NCT06143878
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 5, 2024
- Primary completion
- Mar 13, 2025
- Completion date
- Oct 25, 2027
- First posted
- Nov 22, 2023
- Last posted
- Dec 7, 2023
- Enrollment
- 750
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.